Parathyroid:
A) Primary hyperparathyroidism (pHPT) and parathyroid carcinoma.

Thyroid:
A) Minimally Invasive treatment of thyroid nodes: Radiofrequency ablation (RFA) and Microwave (MW).
B) Risk of malignancy in thyroid nodules classified as TIR3A.
C) Calcitonin assay on thyroid fine needle aspiration (FNA) washout.

Management protocols in the field of Rare Endocrine Diseases - Endo ERN

I am part of the working group on the prevention, surveillance, diagnosis and treatment of Rare Endocrine Diseases, for which Padua has been recognised since 2016 as a “Centre for the Diagnosis and Treatment of Rare Diseases”, within the European Reference Networks (ERN) Endo ERN. Endo ERN comprises eight main thematic groups covering the entire spectrum of congenital and acquired conditions (adrenal, pituitary, thyroid, calcium and phosphorus homeostasis disorders; sexual development disorders; genetic glucose and insulin disorders; genetic neoplastic syndromes; growth disorders and genetic obesity syndromes). The Endo ERN group in Padua involves collaboration between the Endocrinology Unit, the Paediatric Clinic, the Medical Clinic III and the Endocrine Surgery Unit. The aim of the rare diseases working group in the Endo ERN network is to carry out specific research projects and thus improve access to high-quality healthcare for patients with rare endocrine disorders by providing the best diagnostic and treatment approaches through networking in our region and at European level. I am involved in both patient care and scientific research in the clinics dedicated to rare diseases at the Endocrinology Unit, where I manage patients in a multidisciplinary manner, with shared diagnostic and therapeutic pathways and archiving data in specific databases. In particular, my work is included in the management protocols for rare endocrine diseases of the thyroid, such as carcinomas, congenital hypo- and hyperthyroidism, hyperparathyroidism, and multiple endocrine neoplasia (MEN).

Multidisciplinary Autoimmune Polyendocrine Syndromes (APS) Group

I work within a Multidisciplinary APS Group involving the Endocrinology Unit, the Gastroenterology Unit and the Surgical Team that deals with endocrine disorders and gastrointestinal disorders, supporting the active multidisciplinary collaboration that is necessary in the management of patients with APS. Considering the epidemiological data and the complexity of these diseases, the Multidisciplinary SPA Group is focused on improving the management of patients with SPA in terms of both care and scientific research.

5 Publications

Sentinel lymph node mapping: current applications and future perspectives in thyroid carcinoma.
Boschin IM, Bertazza L, Scaroni C, Mian C, Pelizzo MR.Front Med (Lausanne). 2023 Oct 24;10:1231566. doi: 10.3389/fmed.2023.1231566. eCollection 2023.PMID: 37942415.

Medullary thyroid carcinoma.
Pelizzo MR, Mazza EI, Mian C, Merante Boschin I. Expert Rev Anticancer Ther. 2023 Jul-Dec;23(9):943-957. doi: 10.1080/14737140.2023.2247566. Epub 2023 Aug 30.PMID: 37646181 Review.

Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma.
Censi S, Galuppini F, Clausi C, Battheu F, Manso J, Piva I, Corvaglia S, Pedron MC, Mondin A, Iacobone M, Torresan F, Merante Boschin I, Bertazza L, Barollo S, Pennelli G, Mian C.Thyroid. 2024 Dec 27. doi: 10.1089/thy.2023.0482. Online ahead of print.PMID: 38047536.

Women with Autoimmune Thyroiditis Taking Levothyroxine During pregnancy: is iodine supplementation needed?
Censi S, Messina G, Feligiotti E, Clausi C, Piva I, Basso D, Merante Boschin I, Bertazza L, Battheu F, Barollo S, Camilot M, Mian C. Nutrients. 2025 Jan 31;17(3):542. Doi:10.3390/nu17030542. PMID:39940399.

Combining Procalcitonin and calcitonin for the diagnosis of medullary thyroid cancer: a two step approach.
Clausi C, Censi S, Zanin E, Messina G, Piva I, Basso D, Merante Boschin I, Bertazza L, Torresan F, Iacobone M, Battheu F, Barollo S, Arnone JM, Mian C. Clin Endocrinol (Oxf). 2025 Jun 4. Doi: 10.1111/cen.15287. PMID: 40464083.

Funding

2020. DOR: Thyroid nodule with indeterminate cytology TIR3A: follow-up vs surgical treatment.
2021 DOR: Thyroid nodule with indeterminate cytology TIR3A: molecular investigation of TERT and BRAF mutations, follow-up vs surgical treatment.
2024 DOR: Calcitonin measurement in thyroid fine needle aspiration washout fluids: investigating its accuracy in detecting medullary thyroid carcinoma.
2025 DOR: Calcitonin assay on thyroid fine needle aspiration (FNA) washout: our preliminary study and evaluation of its accuracy in the diagnosis of Medullary Thyroid Carcinoma.

People Involved:

Isabella Merante Boschin, MD, Associated Professor
Carla Scaroni , MD, Associated Professor
Caterina Mian, MD, PhD, Associated Professor
Filippo Ceccato, MD, PhD
Maurizio Iacobone, MD, Full Professor
Gianmaria Pennelli, MD, PhD, Associated Professor

Group Members:

Valentina Camozzi, MD
Chiara Sabbadin, MD
Mattia Barbot, MD
Elisa Selmin, MD, resident
Silvia Pinelli, MD, resident
Susi Barollo, Biologist
Loris Bertazza, Biologist